期刊
BLOOD ADVANCES
卷 6, 期 21, 页码 5702-5706出版社
ELSEVIER
DOI: 10.1182/bloodadvances.2021006498
关键词
-
类别
资金
- Italo Monzino Foundation, Milan, Italy
- European Research Council under the European Union?s Horizon 2020 research and innovation program [817997]
- Associazione Italiana Ricerca sul Cancro [IG16722, IG10136, IG24365, IG25739, IG22053]
- Fondazione Umberto Veronesi (Umberto Veronesi Foundation) [2017WXR7ZT, RF2016-02364918]
- Cariplo Foundation (Milan Italy-Project) [2016-0860]
Monoclonal gammopathy of undetermined significance (MGUS) and clonal hematopoiesis (CH) are two preclinical clonal expansions of hematopoietic cells that increase with age. This study analyzed a dataset of 777 older subjects and found that the prevalence of MGUS and CH was 9.6% and 17.3% respectively, with no significant correlation between MGUS and CH.
Monoclonal gammopathy of undetermined significance (MGUS) and clonal hematopoiesis (CH) are 2 preclinical clonal expansions of hematopoietic cells whose prevalence rises with age, reaching almost 10% in people of aged 70 years and older. The increased risk of myeloid malignancies in patients with myeloma is well defined, and the study of the association between CH and MGUS could help explain this phenomenon. Here, we analyzed a fully clinically annotated dataset of 777 older subjects (median age, 91 years) previously screened for prevalence of CH. The prevalence of MGUS and CH was 9.6% and 17.3%, respectively. We detected CH in 9.7% of the patients with MGUS and MGUS in 5.5% of the patients with CH. We did not find a significant correlation between the presence of MGUS and CH. Furthermore, the 2 conditions showed a differential association with clinical and laboratory covariates, suggesting that MGUS and CH may represent age-associated unrelated clonal drifts of hematopoietic cells. Confirmatory studies are needed to assess the relevance of CH in plasma cell disorders. This trial was registered at www.clinicaltrials.gov as #NCT03907553.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据